Literature DB >> 17888707

[Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?].

A Bouyon1, S Hans, C Durdux, M Housset.   

Abstract

The low incidence, the wide histological spectrum and the natural, sometimes slow, evolution of malignant parotid gland tumours do not allow to easily establish the impact of their treatments. At present, clinical data come from retrospective cohort analysis, whereas randomized phase II-III trials are confidential. Moreover conclusions from these studies are controversial. We present here the therapeutic highlights of parotid cancers: surgery, with the particular concern of facial nerve preservation; and adjuvant treatment essentially based on radiotherapy. This review focused on adjuvant care explores the indications and the technical aspects of radiation, as well as the role of concurrent chemotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17888707     DOI: 10.1016/j.canrad.2007.07.002

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  [Predictors of malignancy in the management of parotid tumors: about 76 cases].

Authors:  Brahim Bouaity; Youssef Darouassi; Mehdi Chihani; Mohamed Mliha Touati; Haddou Ammar
Journal:  Pan Afr Med J       Date:  2016-03-16

2.  The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience.

Authors:  Izabela Kordzińska-Cisek; Paweł Cisek; Ludmiła Grzybowska-Szatkowska
Journal:  Cancer Manag Res       Date:  2020-02-11       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.